Dynavax (DVAX) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
February 23, 2023 4:05 PM EST2022 total revenue of $723 million, up 64% from $439 million in 2021HEPLISAV-B® vaccine net product revenue of $126 million, representing 104% growth compared to 2021CpG 1018® adjuvant vaccine net product revenue of $588 million2023 HEPLISAV-B net product revenue anticipated to be between $165 million and $185 million, representing year-over-year revenue growth of approximately 30-47%Increased strength of financial position with year-end cash and investments of $624 millionConference call today at 4:30 p.m. ET/1:30 p.m. PT
EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ --... More
